Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT06918743 (Phase 2, primary completion 2026-03-01) is not yet recruiting with no results posted. No public readout exists. Prior Phase 1 data (different NCT) showed promising PASI/PGA signals and supported further development but does not apply to this exact trial.
Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:25 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as not yet recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific efficacy readout was found. The cited records indicate NCT06918743 was a newly started Phase 2 program in 2025, and a later Hengrui pipeline update listed RSS0393 for plaque psoriasis with reporting-period progress marked as none. That is insufficient to call the trial positive or negative.
Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:47 PM
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public Phase 2 readout was found for NCT06918743. The trial record shows it was still not yet recruiting, and Hengrui’s 2025 interim report lists RSS0393 in plaque psoriasis only as having entered Phase II, not as reporting data. With no trial-specific efficacy readout, outcome cannot be classified positive or negative.
Found Apr 1, 2026, 7:51 PMReviewed Apr 1, 2026, 7:56 PM